<DOC>
	<DOCNO>NCT02517892</DOCNO>
	<brief_summary>This prospective study identify molecular mechanism acquire resistance target therapy patient unresectable metastatic cancer . This protocol study clinical characteristic biopsy tissue patient oncogene-driven cancer previous clinical response target therapy subsequently experience progression disease . The tissue specimen use carry laboratory study explore molecular basis acquire resistance target therapy .</brief_summary>
	<brief_title>A Prospective Trial Study Evolution Clonal Architecture Tumors From Patients Treated With Molecular Targeted Agents</brief_title>
	<detailed_description />
	<criteria>Patients diagnose unresectable metastatic cancer fulfill follow eligibility criterion consider eligible study : 1 . Patient affiliate social security regimen 2 . Therapy target agent ( define appendix 1 ) . 3 . Tumor lesion accessible core biopsy ( malignant effusion represent alternative ) 4 . Patient fully inform , able comply protocol sign informed consent . 5 . Availability initial tumor material ( ideally freeze , nonBouin fix paraffin embed material ) acquire exposure target therapy Note : Patients may receive treatment since treatment target therapy include radiation chemotherapy , undergo study biopsy . 1 . Coagulation abnormality prohibit biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>